Workflow
上海海利生物技术股份有限公司 2025年第三季度报告

Core Viewpoint - The company has announced significant changes regarding its stock incentive plan, including the repurchase and cancellation of certain restricted stocks and stock options due to unmet performance conditions and employee departures [52][64][66]. Financial Data - The company reported a cash dividend of 0.0784 yuan per share, totaling approximately 51.4 million yuan distributed to shareholders [5]. - The total number of shares will decrease from 655,662,200 to 651,904,700 after the repurchase of 3,757,500 restricted stocks [50][66]. Board Meeting and Resolutions - The fifth board meeting was held on October 28, 2025, where several key resolutions were passed, including the approval of the third-quarter report and the adjustment of the stock incentive plan [10][12][58]. - The board approved the appointment of Sigma Accounting Firm for the 2025 financial audit [12]. Stock Incentive Plan Adjustments - The company will repurchase 243,750 restricted stocks due to unmet conditions for the second release period of the stock incentive plan [64][66]. - The repurchase price for restricted stocks has been adjusted to 4.6729 yuan per share, and the exercise price for stock options has been adjusted to 9.4429 yuan per option [61][63]. Upcoming Events - The company will hold a second extraordinary general meeting on November 14, 2025, to discuss the resolutions passed by the board [20][32]. - An investor performance briefing is scheduled for November 21, 2025, to discuss the third-quarter results and address investor inquiries [24][25].